Author:
Tang Juan,Lin Zhiwu,Liu Xingde,Li Biao,Wu Xiaoli,Lv Jing,Qi Xing,Lin Sheng,Dai Chuanqiang,Li Tao
Abstract
AbstractTo analyze the changing trend of CH and CRF values under different influencing factors in T2DM patients. A total of 650 patients with T2DM were included. We discovered that the course of T2DM, smoking history, BMI, and FBG, DR, HbA1c, TC, TG, and LDL-C levels were common risk factors for T2DM, while HDL-C levels were a protective factor. Analyzing the CH and CRF values according to the course of diabetes, we discovered that as T2DM continued to persist, the values of CH and CRF gradually decreased. Moreover, with the increase in FBG levels and the accumulation of HbA1c, the values of CH and CRF gradually decreased. In addition, in patients with HbA1c (%) > 12, the values of CH and CRF decreased the most, falling by 1.85 ± 0.33 mmHg and 1.28 ± 0.69 mmHg, respectively. Compared with the non-DR group, the CH and CRF values gradually decreased in the mild-NPDR, moderate-NPDR, severe-NPDR and PDR groups, with the lowest CH and CRF values in the PDR group. In patients with T2DM, early measurement of corneal biomechanical properties to evaluate the change trend of CH and CRF values in different situations will help to identify and prevent diabetic keratopathy in a timely manner.
Funder
2023 Ziyang Science and Technology Bureau Project
2024 Hebei Province Medical Science Research Project Plan
2022 Key Projects of Sichuan Provincial Science and Technology Plan
Ziyang City Medical Science Project
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Sun, H. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183(2), 109–119 (2022).
2. Pagano, G. et al. Diabetes mellitus and Parkinson disease. Neurology 90(3), 1654–1662 (2018).
3. Zhu, D. et al. Dorzagliatin in drug-naïve patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 28, 965–973 (2022).
4. Yang, W. et al. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial. Nat. Med. 28, 974–981 (2022).
5. Thomas, R. L. et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br. J. Ophthalmol. 99, 64–68 (2015).